Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43
Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and lowers the price target from $46 to $43.
Stocks · News reference
Indivior Q2 2026 Earnings Call: Complete Transcript
Indivior (NASDAQ:INDV) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold players in this sector.
Why Supernus Pharmaceuticals Stock Topped the Market Today
Supernus Pharmaceuticals announced a merger with Indivior Pharmaceuticals in an all-stock deal, creating a combined company with 11 FDA-approved drugs and anticipated $125 million in annual cost synergies. The stock rose 3% despite initial gains of 16%, reflecting cautious optimism. Q2 earnings showed 32% revenue growth to $219 million but a net loss of $58 million, missing earnings estimates while beating revenue forecasts.